Strides Pharma Science Achieves USFDA Approval for Fluoxetine 60 mg Tablets
Significant Development in Fluoxetine Availability
Strides Pharma Science Ltd has announced that its step-down subsidiary, Strides Pharma Global Pte Ltd, has successfully obtained approval from the US Food and Drug Administration (USFDA) for Fluoxetine 60 mg tablets. This new approval is set to expand the company's product line in the antidepressant segment, complementing previous approvals for 10 mg and 20 mg tablets as well as various capsule forms.
Enhanced Product Offering
With this addition, Strides Pharma will now be able to provide patients with a robust portfolio of Fluoxetine options including 10 mg, 20 mg, and 60 mg strengths, tailored to meet diverse patient needs. The total market for Fluoxetine capsules and tablets is estimated at $130 million, indicating a significant opportunity for expansion.
Strategic Manufacturing and Future Plans
The newly approved Fluoxetine tablets will be manufactured at Strides' facility in Puducherry, ensuring quality and reliability. Strides is preparing for an upcoming launch of all three strengths, demonstrating its commitment to serving patients effectively within the antidepressant market.
What is Fluoxetine?
Fluoxetine is a member of the Selective Serotonin Reuptake Inhibitors (SSRIs) class, commonly prescribed for conditions such as Major Depressive Disorder, Obsessive-Compulsive Disorder, Bulimia Nervosa, and Panic Disorder, with or without agoraphobia.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.